Floatz logo

LIDOCAINE

Chemotherapy-induced Peripheral Neuropathy

Hospital Ambroise Paré ParisSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Chemotherapy-induced Peripheral Neuropathy cohort.

Asset / SponsorPhaseRating
Pregabalin
University of Rochester
Phase 4BB
Omeprazole
Aya Mohamed Sadek Elsaid
Phase 3BB
Mecobalamin
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2/3B
Vitamin B6
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2/3B
Sodium Selenite Pentahydrate
Seoul National University Hospital
Phase 3B

View all 46 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →